

# Annual Report 2018

# Foreword

## Welcome to IBioIC's Annual Report 2018.



2018 has been arguably IBioIC's most important year since it began five years ago. We successfully negotiated a Phase II funding process to become one of the first innovation centres to achieve this, thus paving the way for the other innovation centres.

As we embark on the first months of Phase II, we build on a robust performance in Phase I. Amongst our achievements are our ever-growing network of members, both industrial and academic, expanding Skills and Projects programmes, and an annual conference which has grown in five years to become the UK's leading industrial IB conference. Moving forward into Phase II, we will build on our work across five key themes; providing strategic leadership, accelerating commercialisation, developing new value chains, investing in value chains using biotechnology and skilling the necessary workforce.

This report summarises a wide range of achievements and showcases key highlights from the past year. I am delighted that the Centre has continued to grow and develop, even during the logistically complex period in the lead up to our refunding announcement, and has continued to win funding, welcome new members to our network, secure higher TRL projects and expand our skills programme and networking activities.

As I take the reins of IBioIC for this next stage in the journey, I would like to thank my predecessor, Ian Shott, the Governing Board, Scientific and Commercial Advisory Boards for their warm welcome, guidance and support, and I look forward to building on their fantastic work in the coming weeks and months. I have no doubt that the team will approach this new Phase of activity with the same passion, energy and dedication which has marked the Centre's progress so far.

Professor Dame Anne Glover

# Industrial Engagement

In future this content will be reported under the Key Strategic Themes of Providing Strategic Leadership and Developing New Value Chains.



Current IBioIC membership: **122**



**120th Member** milestone reached November 2018



**>850 delegates** hosted across **>10 Member** events



**>450 delegates** attended IBioIC's **Annual Conference 2018**, making it the **leading IB conference in the UK**



Launch of **1st CPD** training programme



**Funding secured** for 3rd year of **Network Integrator Programme**

Effective engagement with industrial stakeholders has been a key factor in IBioIC's success to date. Understanding the needs of industry, providing a platform for collaboration and affording industry the tools to generate innovative solutions has cemented IBioIC's position as the leading Hub for IB in the UK.

IBioIC welcomed its 120th member this year and continued to develop its activities as a hub where members can grow, gain competitive advantage and generate impact. 2018 has been an exciting year for members with many achievements to celebrate including members gaining investment funding, building first-in-class demonstration facilities and advancing their R&D programmes.

*"IBioIC membership, and the benefits afforded, have enabled ScotBio to accelerate its ambitious business plans. We look forward to continuing to work with IBioIC as we scale up production in response to a rapidly growing international market for our products."*

DC VAN ALSTYNE, CEO, SCOTBIO

*"IBioIC membership, and funding won through the project and studentship competitions, has allowed Synpromics to advance its R&D programme and, in collaboration with leading biopharmaceutical companies, help solve key industry problems with its synthetic promoters thereby enabling the development of next generation technologies, medicines and diagnostics."*

ROSHEEN CAW, DIRECTOR OF BUSINESS ADMINISTRATION & COMPANY SECRETARY, SYNPROMICS

*"The IBioIC Annual conference is the go to IB event of the year and is unrivalled by any other in the UK."*

JEN VANDERHOVEN, VICE PRESIDENT OF GLOBAL BUSINESS CHANGE, FUJIFILM DIOSYNTH TECHNOLOGIES

# Projects

In future this content will be reported under the Key Strategic Theme of Investing in IB.



Supported a total of 49 projects over the past 5 years



IBioIC's projects programme had an accumulated value of £11.7M

Investing in biotechnology through pump-prime funding of innovative projects, led by industry in collaboration with academia, will remain a key activity in Phase II. The Centre continues to engage with HEI Partners and the BBSRC NIBBs to leverage and extend funding for this work.

**JUNE:**  
launch of first IBioIC jointly funded project with another Scottish Innovation Centre (Construction Scotland Innovation Centre, CSIC)

**AUGUST:**  
launch of Connecting Innovation Centres project, focusing on closer working between the Scottish IC project teams

**AUGUST:**  
launch of IBioIC's first Phase II competition 'IB Prime Accelerator'

**NOVEMBER:**  
'Exploring Opportunities in Blue Biotech and Aquaculture'; first IBioIC Phase II workshop in partnership with Highlands and Islands Enterprise, SAIC and ZWS

## Key Priorities:

- Supporting the successful spin-out of new companies
- Securing higher TRL projects through public sector programmes and private investment

"Alfacyte is a pre-clinical micro-business in the biotech space, where funding is limited and we need to focus on developing our lead asset into a revenue-generating concern. However, with 4 patents and an unrivalled bank of knowledge, we also have tremendous potential to innovate. Support from the IBioIC Accelerator Project has enabled us to pursue our long-term goal to develop a platform that will generate specific, targeted molecules with therapeutic potential. It has given us the opportunity to collaborate with Professor Kathryn Ball and other leading academics in Cancer Research at Edinburgh University, where we continue to benefit from their extensive experience. The resulting solution, will help to propel Alfacyte into the cancer immunotherapy market".

GILLIAN BROWN, CEO, ALFACYTE

"The Antibody Company (TAC), a contract manufacturer of monoclonal antibodies, is collaborating with academics from the University of Strathclyde to develop immuno-diagnostic, point of care test (POCT) kits. The project takes advantage of TAC's expertise in developing antibodies and the academics novel conjugation technology. The pilot work, funded by the University of Strathclyde, proved very successful, so TAC undertook extensive market research, partly funded by Scottish Enterprise to identify key areas in which to develop POCT kits.

TAC has been able to continue and develop this collaboration with academics from the University of Strathclyde thanks to funding from IBioIC/ESPRC after receiving an IB Accelerator Project grant. We are now in the late stages of developing our first device".

ERIC WAGNER, DIRECTOR, THE ANTIBODY COMPANY


# Equipment Centres

In future this content will be reported under the Key Strategic Theme of Accelerating Commercialisation.

IBioIC's Equipment Centres have linked closely with customers and to each other to provide a comprehensive bioprocess development and de-risking service.

The facilities have supported a diverse range of work programmes, from media optimisation and down-scale culture improvement projects to fermentation scale-ups from shake flask to 30L scale with integrated downstream processing.

A wide range of microorganisms including plant cells, microalgae and an extensive selection of bacterial species, including GM bacteria, have been successfully cultivated within the facilities.



# Skills

In future this content will be reported under the Key Strategic Theme of Skilling the Workforce.

With almost 200 students now engaged in our educational programmes, IBioIC is fast on its way to supporting the next generation of IB practitioners enter the workforce and become future leaders. They graduate from our programmes industry ready; with a sound knowledge base from the best teachers and researchers in Scotland and the North of England as well as critical industry experience making them highly sought after employees.

"Ten-week projects are great opportunity to engage with upcoming biotechnology stars and to give them a shot at real life industrial biotechnology labs, which definitely helps in their future career".

MONIKA TOMECKA, COO, UFRACIONS



Over 80% of MSc students from the 2016/17 cohort are employed or undertaking further education



20% of MSc students in the current cohort are international (80% Scotland/EU)



Industry readiness training and work placements demonstrably contribute to high employment rates



First cohort of PhD students are completing their degrees and entering the IB workforce



The Skills team are actively engaged in partnering graduates at HND, MSc and PhD level with potential employers

# Finance and Funding

With continued increase in centre activities, financial year 2017-18 saw a 27% increase in the value of total activity from £6.8m to £8.7m. The combined cost of Core Overheads and Direct Programme Support remained flat, but delivered significant increases of 40% and 35% in the Skills and Project programmes respectively.

The percentage of spend funded by non-SFC sources increased by 14% on the previous financial year to 66%. This includes cash income and grants received directly by the centre and also external contributions of cash, grant and in-kind input to IBioIC activities from partner organisations.



The percentage of spend funded by industry and other grant income is increasing year-on-year, with 53% of activity in 2016-17 funded from non-SFC sources compared to 33% two years ago. This trend is forecast to continue into next year.

### Key Funding Priorities:

- Supporting members in UK and EU funding calls
- Reassuring EU stakeholders of the underwriting guarantees by the UK Treasury for European funded projects

In 2018, IBioIC partnered with a number of external funding organisations like Zero Waste Scotland to enhance the portfolio of collaborative research projects across its members and continued to play a key role in the BioBased Industries Consortium.

During 2017/18 the Centre has been awarded £13M external funding with a total project value of over £14.3M.



# New Governing Board members in 2018

In 2018, the IBioIC Governing Board has welcomed six new members and a new Chair, bringing the total number of Governing Board members to 17. Our new members were appointed following an open call and bring with them a wealth of industry experience and ensure that IBioIC's members, partners and stakeholders can be confident that the Centre is diligently governed, delivering on its promises, and is at the forefront of Industrial Biotechnology innovation on an international stage.

<b>Professor Dame Anne Glover</b>	Chair - IBioIC Governing Board	Aug 2018 – July 2021*
<b>Darren Budd</b>	Commercial Director - BASF	Jan 2018 – Jan 2021*
<b>Tim Davies</b>	Founder – Rubus Scientific	Jan 2018 – Jan 2021*
<b>Heleen Goorisson</b>	Vice President Global R&D - Corbion	Jan 2018 – Jan 2021*
<b>David Robertson</b>	Chair - 3fBio	Jan 2018 – Jan 2021*
<b>Stuart West</b>	Non Executive Director – BioCatalysts	Jan 2018 – Jan 2021*
<b>Stephen Wise</b>	Director of BioEnergy – Viridian Group	Jan 2018 – Jan 2021*

## Current Governing Board Members

<b>Ted Chapman</b>	Biotechnology Development Director - GSK	Dec 2016 – Dec 2019*
<b>Sandy Dobbie</b>	Chair – MBL	Jan 2014 – Jan 2020
<b>Ian Fotheringham</b>	CEO - Ingenza	Jan 2014 – Jan 2020
<b>Claire Halpin</b>	Professor – University of Dundee	Dec 2016 – Dec 2020
<b>Roger Kilburn</b>	CEO - IBioIC	Jan 2014**
<b>Ian Little</b>	Site Business Development Manager - INEOS	Jan 2014 – Jan 2020
<b>David Littlejohn</b>	Dean of Science - Strathclyde	Sept 2015 – Sep 2019
<b>Mark Simmers</b>	CEO – Celtic Renewables	Nov 2015 – Nov 2021
<b>Joyce Tait</b>	Professor – University of Edinburgh	Dec 2016 – Dec 2020
<b>Bob Tooze</b>	CEO - Drochaid	Nov 2015 – Nov 2021

\* CAN SERVE A SECOND TERM.  
 \*\* THE IBIOIC CEO IS A GOVERNING BOARD MEMBER FOR THE PERIOD (S)HE IS EMPLOYED IN THIS ROLE.


## Scientific Advisory Board

The SAB welcomed Iain Hunter and Stephen Roe as the new Chair and Vice Chair, replacing Michele Stanley and Nik Willoughby respectively.

Stephen Roe is currently leading a review of the effectiveness of the SAB and will implement changes in 2019.

## Commercial Advisory Board

The CAB welcomed Douglas McKenzie as the new Chair in 2018.



Prepared by:



[WWW.IBIOIC.COM](http://WWW.IBIOIC.COM)

\*Content correct at time of printing



Supported by The Scottish Funding Council,  
Highlands and Islands Enterprise and  
Scottish Enterprise.